Discontinuation of tyrosine kinase therapy in CML

详细信息    查看全文

• 作者：Francois-Xavier Mahon (1) (2)
  
  1. Laboratoire d鈥檋茅matologie ; CHU de Bordeaux ; Bordeaux ; France
  2. Laboratoire H茅matopo茂猫se Leuc茅mique et Cible Th茅rapeutique ; INSERM 1035 ; Universit茅 Bordeaux ; 146 Rue L茅o Saignat ; 33076 ; Bordeaux Cedex ; France
  
• 关键词：Chronic myeloid leukemia ; Deep molecular response ; Treatment ; free remission
• 刊名：Annals of Hematology
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：94
• 期：2-supp
• 页码：187-193
• 全文大小：346 KB
• 参考文献：1. National Comprehensive Cancer Network (2012) Chronic Myelogenous Leukemia. NCCN Clinical Practice Guidelines in Oncology; v1.2013
  2. Baccarani, M, Deininger, MW, Rosti, G, Hochhaus, A, Soverini, S, Apperley, JF (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122: pp. 872-884 CrossRef
  3. Rea, D, Rousselot, P, Guilhot, J, Guilhot, F, Mahon, FX (2012) Curing chronic myeloid leukemia. Curr Hematol Malig Rep 7: pp. 103-108 CrossRef
  4. Rousselot, P, Huguet, F, Rea, D (2007) Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109: pp. 58-60 CrossRef
  5. Mahon, FX (2012) Is going for cure in chronic myeloid leukemia possible and justifiable?. Hematol Am Soc Hematol Educ Program 2012: pp. 122-128
  6. Mahon, FX, Rea, D, Guilhot, J, Guilhot, F, Huguet, F, Nicolini, F (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11: pp. 1029-1035 CrossRef
  7. Mahon F, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini FE et al (2013) Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: update results of the STIM Study. Blood (ASH Annual Meeting Abstracts);122, [abstract 255]
  8. Ross, DM, Branford, S, Seymour, JF (2010) Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24: pp. 1719-1724 CrossRef
  9. Ross, DM, Branford, S, Seymour, JF, Arthur, C, Schwarer, AP, Dang, P (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122: pp. 515-522 CrossRef
  10. Takahashi, N, Kyo, T, Maeda, Y, Sugihara, T, Usuki, K, Kawaguchi, T (2012) Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica 97: pp. 903-906 CrossRef
  11. Cortes, J, O鈥橞rien, S, Kantarjian, H (2004) Discontinuation of imatinib therapy after achieving a molecular response. Blood 104: pp. 2204-2205 CrossRef
  12. Mauro, MJ, Druker, BJ, Marziaz, RT (2004) Divergent clinical outcome in twp CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 28: pp. S71-S73 CrossRef
  13. Merante, S, Orlandi, E, Bernasconi, P (2005) Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 90: pp. 979-981
  14. Michor, F, Hughes, TP, Iwasa, Y (2005) Dynamics of chronic myeloid leukaemia. Nature 435: pp. 1267-1270 CrossRef
  15. Mahon FX, Nicolini F, No毛l MP, Escoffre M, Charbonnier A, Rea D, Dubruille V, Varet B, Legros L, Guerci A, Etienne G, Guilhot F, Dulucq S, Rousselot P, Guilhot J (2013) Preliminary Report Of The STIM2 Study: a multicenter Stop Imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib. Blood (ASH Annual Meeting Abstracts) [abstract 654]
  16. Rousselot, P, Charbonnier, A, Cony-Makhoul, P (2014) Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 32: pp. 424-430 CrossRef
  17. Saussele, S, Richter, J, Guilhot, J, M眉ller, MC, Dietz, C, Porkka, K (2014) First interim analysis of a Pan-European Stop trial using standardized molecular criteria: results of the EURO-SKI trial. 19th Congress of the European Hematology Association, Milan, Italy, June 12鈥?5, 2014. Haematologica 99: pp. LB-6214
  18. Mahon FX, Baccarani M, Mauro M et al (2014) Treatment-free remission following nilotinib in patients with chronic myeloid leukemia in chronic phase: ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath ASCO meeting 2014. J Clin Oncol 32:5s, (suppl; abstr TPS7124)
  19. Stein, AM, Bottino, D, Modur, V (2011) BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment. Clin Cancer Res 21: pp. 6812-6821 CrossRef
  20. Horn, M, Glauche, I, M眉ller, MC, Hehlmann, R, Hochhaus, A, Loeffler, M, Roeder, I (2013) Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Blood 121: pp. 378-384 CrossRef
  21. Cross, NCP, White, H, M眉ller, MC, Saglio, G, Hochhaus, A (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26: pp. 2172-2175 CrossRef
  22. Branford, S, Seymour, JF, Grigg, A, Arthur, C, Rudzki, Z, Lynch, K (2007) BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 13: pp. 7080-7085 CrossRef
  23. Melo, JV, Ross, DM (2011) Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?. Hematol Am Soc Hematol Educ Program 2011: pp. 136-142 CrossRef
  24. Biernaux, C, Loos, M, Sels, A (1995) Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 8: pp. 3118-3122
  25. Bose, S, Deininger, M, Gora-Tybor, J (1998) The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 92: pp. 3362-3367
  26. Deininger, M (2011) Hematology: curing CML with imatinib鈥攁 dream come true?. Nat Rev Clin Oncol 3: pp. 127-128 CrossRef
  27. R茅a D, Rousselot P, Nicolini F, Legros L, Tulliez M, Giraudier S, Cony-Makhoul P, Guilhot F, Mahon FX (2011) Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia patients with stable undetectable BCR-ABL transcripts: results from the French CML group (FI-LMC) Blood (ASH) 2012: Abstract 9168. Rea D, et al. Blood.;118(21) [abstract 604]
  28. Yhim, HY, Lee, NR, Song, EK, Yim, CY, Jeon, SY, Shin, S (2012) Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response. Leuk Res 36: pp. 689-693 CrossRef
  29. Branford, S, Yeung, DT, Ross, DM (2013) Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 121: pp. 3818-3824 CrossRef
  30. Falchi, L, Kantarjian, HM, Wang, X (2013) Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 88: pp. 1024-1029 CrossRef
  31. Hehlmann, R, M眉ller, MC, Lauseker, M (2014) Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 32: pp. 415-423 CrossRef
  32. Rea D, Dulphy N, Henry G, J Guilhot J, Guilhot F, Franck E. Nicolini, Legros L, Rousselot Ph, Mahon FX, Toubert A (2013) Low natural killer (NK) cell counts and functionality are associated with molecular relapse after imatinib discontinuation in patients (pts) with chronic phase (CP)-chronic myeloid leukemia (CML) with undetectable BCR-ABL transcripts for at least 2 years: preliminary results from immunostim, on behalf of STIM investigators. Blood (ASH Annual Meeting Abstracts); 122 (suppl): [abstract 856)
  33. Ilander MM, Olsson-Str枚mberg U, L盲hteenm盲ki H et al (2013) Disease Relapse After TKI Discontinuation in CML is related both To low number and impaired function of NK-cells: data from Euro-SKI. Blood (ASH Annual Meeting Abstracts); 122 (suppl): [abstract 379)
  34. Mahon, FX, Delbrel, X, Cony-Makhoul, P (2002) Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 20: pp. 214-220 CrossRef
  35. Goldman, J, Gordon, M (2006) Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?. Leuk Lymphoma 47: pp. 1-7 CrossRef
  36. Gallipoli, P, Abraham, SA, Holyoake, TL (2011) Hurdles toward a cure for CML: the CML stem cell. Hematol Oncol Clin N Am 25: pp. 951-966 CrossRef
  37. Rea, D, Rousselot, P, Guilhot, J (2012) Curing chronic myeloidleukemia. Curr Hematol Malignancy Rep 7: pp. 103-108 CrossRef
  38. Hantschel, O, Warsch, W, Eckelhart, E (2012) BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol 8: pp. 285-293 CrossRef
  39. Chen, Y, Peng, C, Sullivan, C (2010) Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia. Anti Cancer Agents Med Chem 10: pp. 111-115 CrossRef
  40. Zhang, B, Strauss, AC, Chu, S (2010) Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 17: pp. 427-442 CrossRef
  41. Li, L, Wang, L, Li, L (2012) Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21: pp. 266-281 CrossRef
  42. Hurtz, C, Hatzi, K, Cerchietti, L (2011) BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med 208: pp. 2163-2174 CrossRef
  43. Kleppe, M, Levine, RL (2012) Targeting beta-catenin in CML: leukemiastem cells beware!. Cell Stem Cell 10: pp. 351-353 CrossRef
  44. Dierks, C, Beigi, R, Guo, GR (2008) Expansion of Bcr-Ablpositive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 14: pp. 238-249 CrossRef
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Hematology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0584

文摘

Over the past decade, a broad array of drugs designed to selectively inhibit protein tyrosine kinases (tyrosine kinase inhibitors or TKIs) have emerged as novel therapies for cancer patients. Chronic myeloid leukemia (CML) is one of the best examples of successful targeted therapy with a TKI. The overall survival of CML patients who respond to treatment is close to that of the healthy population. The response in many patients is so profound that it is possible to consider stopping their treatment and with time, the number of patients in this group has increased to the point where the issue of treatment cessation has become of utmost importance. This has led to the development of a new concept in the evaluation of CML entitled treatment-free remission. It will be the criterion to evaluate the success of future clinical trials, especially if we want to improve the management of the disease to the point where we can claim to have cured CML.